New ecm record created in order to update legacy complaint (b)(4).Asr revision to take place (b)(6) 2012.Asr xl acetabular system (left).Reason(s) for revision: alval/soft tissue reaction.Update ad 26 jul 2019: dint (b)(4) has been reopened under (b)(4) due to receipt of surgeon confirmation form indicating that the patient was revised to address pain and alval/soft tissue reaction.Added patient initials, event date, patient harm and manufacture date to all ips.Corrected revision date.Doi: (b)(6) 2007, dor: (b)(6) 2011 (left hip).
|
Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.Product complaint # (b)(4).Investigation summary: the asr platform was voluntarily recalled from the market in august 2010, and the asr product codes are now considered inactive.Further investigation of this individual incident will not be undertaken.The investigation regarding the root cause(s) and/or corrective actions was conducted under mdd capa- 001226.Ongoing post market surveillance is conducted per our procedures for this product.If information is obtained that was not available for the initial medwatch, a follow-up medwatch, a follow-up medwatch will be filed as appropriate.
|